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OBJECTIVES: The inflammatory response is a key mechanism of neuronal damage and loss during acute ischemic
stroke. Hypothermia has shown promise as a treatment for ischemic stroke. In this study, we investigated the
molecular signaling pathways in ischemic stroke after hypothermia treatment.
METHODS: Cyclin-dependent kinase 5 (CDK5) was overexpressed or silenced in cultured cells. Nuclear
transcription factor-kB (NF-kB) activity was assessed by measurement of the luciferase reporter gene. An
ischemic stroke model was established in Sprague–Dawley (SD) rats using the suture-occluded method. Animals
were assigned to three groups: sham operation control, ischemic stroke, and ischemic stroke + hypothermia
treatment groups. Interleukin 1b (IL-1b) levels in the culture supernatant and blood samples were assessed by
ELISA. Protein expression was measured by Western blotting.
RESULTS: In HEK293 cells and primary cortical neuronal cultures exposed to hypothermia, CDK5 overexpression
was associated with increased IL-1b, caspase 1, and NF-kB levels. In both a murine model of stroke and in
patients, increased IL-1b levels were observed after stroke, and hypothermia treatment was associated with
lower IL-1b levels. Furthermore, hypothermia-treated patients showed significant improvement in neurophy-
siological functional outcome.
CONCLUSIONS: Overall, hypothermia offers clinical benefit, most likely through its effects on the inflammatory
response.
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’ INTRODUCTION
Ischemic stroke is one of the leading causes of mortality
worldwide and the number one cause of death in the nor-
thern area of China. Inflammatory responses resulting from
ischemic stroke have been recognized as a key factor in the
pathology of ischemic stroke. Previous studies have shown
that the serum interleukin 1b (IL-1b) level is elevated in
ischemic stroke patients, indicating activation of the immune
system, which is associated with infiltration of immune and
inflammatory cells into the central nervous system, possibly
mediating neuronal damage in the brain.
Hypothermia is a promising treatment for stroke. Studies
of experimental ischemic stroke models have found that the
benefits of hypothermia treatment could be the result of
a range of biological processes that are modulated by
temperature, including reduced oxidative stress, proteolysis,
and excitotoxicity (1). More importantly, hypothermia treat-
ment has long been established to reduce the infarction size
and cell death due to necrosis and apoptosis (2). Recent
studies indicate that therapeutic hypothermia regulates the
expression of both pro-inflammatory and anti-inflammatory
cytokines, implying a close association between hypothermia
and inflammatory responses in the pathogenesis of ischemic
stroke (3).
Interleukin 1b (IL-1b), a pro-inflammatory cytokine and
a core molecule of inflammasomes, has been found to be
associated with neuronal necrosis and apoptosis. Cyclin-
dependent kinase 5 (CDK5), in turn, has been reported
to mediate the activation of the neuronal inflammasome,
accompanied by the expression of core inflammasome
molecules, such as caspase 1 (4). Furthermore, hyperactivity
of CDK5, caused by the conversion of the CDK5 activator
p35 to p25, has been reported to mediate neuronal death in
ischemic stroke (5). Therefore, during ischemic stroke, CDK5
may induce activation of the inflammasome, which then
leads to neuronal damage. The activation of nuclear trans-
cription factor-kB (NF-kB) has been noted in infarcted
cerebral areas during the early stage of ischemic stroke (6).
NF-kB is involved in neuronal inflammation after cerebral
stroke, but the potential association between CDK5 and
NF-kB remains poorly understood.DOI: 10.6061/clinics/2019/e938
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In this study, we investigated the molecular mechanisms
of the inflammatory response in ischemic stroke, particu-
larly the correlation between the levels of CDK5 and various
inflammatory molecules, including IL-1b, NF-kB, and caspase
1. Moreover, we further explored the effectiveness of hypo-
thermia as a treatment in a cohort of ischemic stroke patients.
’ MATERIALS AND METHODS
The animal experiments were approved by the Animal
Ethical Committee of the local hospital.
Reagents
Neurobasal medium, B27 supplement, high-glucose Dul-
becco’s Modified Eagle Medium (DMEM), and fetal bovine
serum (FBS) were purchased from Gibco (Grand Island, NY,
USA). pcDNA3.0, pcDNA-CDK5, and GFP-p25 plasmids
were obtained from Addgene (Cambridge, MA, USA). An
NF-kB luciferase reporter plasmid was purchased from Beyo-
time Institute of Biotechnology (Shanghai, China). Lipofecta-
mine 2000 transfection reagent and Opti-MEMI medium were
obtained from Invitrogen (Carlsbad, CA, USA). Etoposide and
roscovitine were obtained from Sigma-Aldrich (St. Louis, MO,
USA). A luciferase reporter gene assay kit was purchased
from Roche (Basel, Switzerland). The 96-well plate used for
the luciferase reporter gene test was purchased from Greiner
(Lud-wigsburg, Germany). Other cell culture plates were
purchased from Corning (Corning, NY, USA). The primary
antibody against caspase 1 was obtained from Abcam (Cam-
bridge, MA, USA). Primary antibodies, including anti-CDK5,
anti-phosphorylated (p)-CDK5, anti-IL-1b, and anti-b-actin
antibodies, were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Goat anti-rabbit and goat-anti-mouse
horseradish peroxidase (HRP)-conjugated secondary antibo-
dies were purchased from Jackson Immuno Research (West
Grove, PA, USA).
Cell culture and transfection
For primary cortical neuronal culture, Sprague–Dawley
(SD) rats (prenatal 16–18 days old) were euthanized, and
their cortex tissues were collected in D-Hanks solution. The
cortex tissues were then digested with trypsin, and the cells
were resuspended in neurobasal medium containing B27
supplement and glutamine. The single-cell suspension was
then transferred to a 6-well culture plate precoated with
poly-D-lysine at a density of 2  106 cells/well (in 2 mL cul-
ture medium). The cells were incubated at 37oC for 7 days for
further experiments. HEK293 cells were cultured in high-
glucose DMEM that contained 10% FBS in an incubator
at 37oC with 5% carbon dioxide. Transfection was conducted
when cells reached 85% confluency according to the manu-
facturer’s instructions for Lipofectamine 2000. Cells were
transfected with the NF-kB luciferase reporter plasmid.
Twenty-four hours later, cells were transfected with pcDNA-
CDK5 and GFP-p25 plasmids. Control cells were subjected
to NF-kB luciferase reporter plasmid transfection followed
by transfection with a pcDNA3.0 plasmid. Forty-eight hours
after transfection, cells were lysed, and substrates were added
according to the manufacturer’s instructions (Roche). The
absorption was recorded on a fluorescence microplate, and
NF-kB activity was analyzed.
siRNA-CDK5 and siControl were purchased from Gene-
pharma, Shanghai, China. The sequences of siRNAs were as
follows: siRNA-CDK5,50-GUUCAGCCCUCCGGGAGAUTT-30;
SiControl, 50-GAGACCCTATCCGTGATTA-30. For RNA silen-
cing, cortical neurons were transfected with siRNAs using
Lipofectamine 2000 transfection reagent according to the
manufacturer’s instructions. Twenty-four hours after transfec-
tion, cells were used for experiments.
Murine model of ischemic stroke
Male SD rats weighing 350-380 g were used to establish the
rodent ischemic stroke model. The animal experiments were
approved by the Animal Ethical Committee of the local
hospital. The ischemic stroke model was established using the
suture-occluded method developed by Longa (7). Three hours
after the surgery, rat neurophysiology was evaluated by
postural reflex, and unawake or dead animals were excluded
from analysis. Rats without autonomous activity or defects in
neuronal function were not included in the study. The post-
ural reflex was rated on a three-point scale, and animals that
scored X1 point were considered ischemic stroke animals.
Animals were assigned to three groups: sham operation
control (n=12), ischemic stroke (n=12), and ischemic stroke+
hypothermia treatment (n=12). In the ischemic stroke +
hypothermia treatment group, rats were treated with a
cooling blanket at 3 h after surgery.
Enzyme-linked immunosorbent assay (ELISA)
Blood samples were collected from animals in the ischemic
stroke (n=6) and ischemic stroke + hypothermia treatment
(n=6) groups at 6 h after operation. Control animals were fed
for 2 days, and blood samples were collected from animals
(n=6) under anesthesia. Serum samples were prepared
immediately after blood collection. The IL-1b level in serum
derived from the three experimental groups was assessed by
ELISA.
Western blotting
Primary cultured neurons were collected and lysed by
radioimmunoprecipitation assay (RIPA) lysis buffer. The
intracerebral ischemic penumbra was harvested from rats
in the ischemic stroke and ischemic stroke + hypothermia
treatment groups at 6h after surgery or from control rats.
Tissue samples were minced and lysed, and an equal amount
of protein was loaded and subjected to gel electrophoresis.
Protein samples were then transferred to a polyvinylidene
difluoride (PVDF) membrane, which was incubated with
primary antibodies against caspase 1 (1:1000 dilution), CDK5
(1:1000), p-CDK5 (1:1000), or b-actin (1:5000) at 4oC over-
night. After the membrane was washed with Tris-buffered
saline plus Tween-20 (TBS-T) three times, it was further
incubated with a secondary antibody (1:20,000) for another
1 h at room temperature. After the membrane was washed,
the bands were visualized using the BeyoECL Plus kit accor-
ding to the manufacturer’s instructions (Beyotime Institute
of Biotechnology). The densities of the bands of interest were
analyzed by ImageJ software.
Cohort study of hypothermia treatment
The cohort study included a total of 24 patients with acute
cerebral infarction who were treated in the Department of
Neurology, the First Affiliated Hospital of Harbin Medical
University, Heilongjiang, China, from November 1, 2015 to
December 31, 2015. Patients were randomly divided into two
groups, including the standard of care group (n=12) and the
standard of care + hypothermia treatment group (n=12).
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In addition, a total of 12 gender- and age-matched healthy
controls who underwent physical examination at the First
Affiliated Hospital of Harbin Medical University, Heilong-
jiang, China were recruited. Informed consent forms were
collected from all patients. Ethical approval for this study
was granted by the local hospital.
Patients who were treated with hypothermia received
cooling treatment for 24 h using a focal mild hypothermia
therapy device (Harbin, China) wrapped around the head
that maintained the tympanic temperature at 33-35oC, which
was measured with an OMRON thermometer (Omron Dalian
Co., Ltd., China). After therapy, the body temperature was
gradually restored to 36.5-37.5oC within 12-20 h, increasing by
1oC every 4-6 h.
Venous blood samples (2 mL) were collected from the
patients on the second day after the stroke. Morning fasting
venous blood samples (2 mL) were collected from control
cases. The serum IL-1b level was assessed by ELISA.
Statistical analyses
All of the data were presented as the mean ± standard
error of the mean (SEM). The statistical analyses were
performed with two-tailed Student’s tests. Analyses were
carried out by GraphPad Prism5 software. p-value of less than
0.05 was considered to be statiscally significant, *po0.05.
’ RESULTS
Inflammatory molecular signaling pathway in
neuronal cultures
We examined the correlation between CDK5 and NF-kB,
a molecule known to mediate inflammatory responses. HEK
293 cells were transfected with CDK5 together with the CDK5
activator p25 plasmids (CDK5/p25) or pcDNA3.0 plasmid,
a negative control, and NF-kB activity was assessed by
measurement of the luciferase reporter gene.
The NF-kB level in cells transfected with CDK5/p25 was
significantly higher than that in cells transfected with
pcDNA3.0 (Figure 1A). We further examined the correlation
between CDK5 and NF-kB in primary cortical neuron cul-
tures. Cultured neurons were treated with etoposide (ETOP)
to stimulate CDK5 activation or ETOP and siCDK5, and
untreated neurons were used as a control. The activity of NF-
kB, as assessed with the luciferase reporter gene assay,
was negligible in control cells (Figure 1B). In contrast, ETOP
treatment induced substantial NF-kB transcription, which
was significantly reduced by cotreatment with siCDK5.
Thus, CDK5 may activate NF-kB.
In primary cortical neuronal cultures, inflammatory stimu-
lation was associated with an increase in the IL-1b level.
Here, neuronal cultures were treated with lipopolysaccharide
(LPS) and adenosine triphosphate (ATP) or LPS and alum,
and the IL-1b level in the supernatant of the culture was
assessed via ELISA. Cultures treated with either LPS with ATP
or LPS with alum had a significantly higher IL-1b level in the
supernatant than untreated control cultures (po0.01; Figure 2).
Figure 1 - CDK5 activated NF-kB in HEK293 cells and primary cultured cortical neurons. (A) HEK293 cells were transfected with
pcDNA3.0 or CDK5 plus p25. (B) Cultured cortical neurons were treated with ETOP to stimulate CDK5 activation or ETOP and siCDK5,
and untreated neurons were used as controls. NF-kB activity was measured using a luciferase reporter gene assay. *po0.05; **po0.01.
Figure 2 - IL-1b was produced in cortical neurons in response to
inflammatory stimuli. Cultured primary cortical neurons were
treated with LPS and ATP or LPS and alum, and the IL-1b level
in the supernatant of the culture was assessed with ELISA.
*po0.05; **po0.01.
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Next, we examined the correlation between CDK5 and
IL-1b. Cultured primary cortical neurons were treated with
ETOP, ETOP plus roscovitine (ROS), a CDK5 inhibitor, and
ETOP plus siCDK5. Untreated cells were used as the control
group. ELISA revealed that the IL-1b level in the supernatant
of the cell culture was significantly higher in the ETOP-treated
cells than in the control group (po0.01; Figure 3A). Blocking
CDK5 activity with either ROS or siCDK5 significantly reduced
the IL-1b level (po0.05). There was no significant difference in
the protein expression of pro-caspase 1 (p45) among the three
groups as assessed via Western blotting (Figure 3B). The level
of activated caspase 1 (p20) in these cells was consistent with
the IL-1b level; the p20 subunit level was significantly higher
in ETOP-treated cells than in the control group (po0.01), and
treatment with either ROS or siCDK5 significantly reduced the
IL-1b level (po0.05).
IL-1b and CDK5 levels in a murine model of
ischemic stroke
We next investigated the correlation between hypothermia
treatment and IL-1 and CDK5 levels in a rat model of
ischemic stroke. Ischemic stroke was surgically induced in
rats, and rats in the hypothermia treatment group were cooled
immediately after the surgery. Both the serum IL-1b content
and IL-1b level in the brain tissue assessed by ELISA were
significantly higher in ischemic stroke rats than in rats in the
sham surgery group (po0.01; Figure 4A and Figure 4B).
Hypothermia treatment significantly reduced the increase in
IL-1b (po0.05 compared to ischemic stroke).
In addition, the protein expression levels of CDK5 and
p-CDK5 in the intracerebral ischemic penumbra area and
normal brain tissues were analyzed. As shown in Figures 4C
and 4D, there was no obvious change in the overall expres-
sion of CDK5 among the three experimental groups. How-
ever, the level of p-CDK5 was significantly upregulated in
the intracerebral ischemic penumbra derived from animals
with ischemic stroke compared with that in the penumbra
from animals who underwent sham surgery (po0.05). Note
that treatment with hypothermia greatly reversed the eleva-
tion in p-CDK5 in the intracerebral ischemic penumbra in
ischemic rats (po0.05).
Serum IL-1b level in a cohort of ischemic patients
treated with hypothermia
This cohort study included 24 patients who had experi-
enced acute ischemic stroke and were randomized into groups
treated with hypothermia with standard of care or standard of
care alone and 24 healthy volunteers. There was no signifi-
cant difference in the age between the two cohorts (Table 1;
p40.05). Neurophysiological function was assessed using the
National Institutes of Health Stroke Scale (NIHSS). At the start
of treatment, hypothermia-treated patients scored 13.8±7.8,
and the standard of care patients scored 14.2±7.2 (p40.05).
After therapy, the decrease in the NIHSS score was 2.6±1.3 in
the standard of care group and 3.9±1.6 in the hypothermia-
treated patients (po0.05).
The serum IL-1b level was assessed in all patients on the
second day after the stroke. The IL-1b level was significantly
higher in patients with stroke than in healthy volunteers
(po0.01; Figure 5). Furthermore, hypothermia-treated patients
showed a significantly lower serum IL-1b than patients in the
standard of care only group (po0.05).
’ DISCUSSION
Hypothermia as a treatment option for ischemic stroke has
shown promise. This study examined the molecular mechan-
ism of the inflammatory response and the possible effects
of hypothermia on the signaling pathway. We found that in
cultured neurons, activation of CDK5 was associated with
increased levels of key inflammatory molecules, including
IL-1, NF-kB, and caspase 1. These findings are consistent
with available studies of inflammatory responses.
A high body temperature is associated with a larger infarct
size and poor functional outcome in patients with acute
Figure 3 - CDK5 provoked the production of IL-1b in cortical
neurons. Cultured primary cortical neurons were treated with
10 mM ETOP or 10 mM ETOP plus ROS, a CDK5 inhibitor, for 12 h.
For RNA interference, cells were pretreated with siCDK5 for 24 h,
followed by 10 mM ETOP plus siCDK5 incubation for another
12 h. Untreated cells were used as the control group. (A) The IL-
1b level in the supernatant of the cell culture was assessed by
ELISA. (B) The protein expression levels of pro-caspase 1 (p45)
and activated caspase 1 (p20) were assessed by Western blotting.
*po0.05; **po0.01.
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ischemic stroke (8). The effectiveness of therapeutic hypother-
mia for the management of ischemic stroke has been well
documented in several animal studies as well as preclinical
trials (9,10). In clinical trials, the use of hypothermia after
conventional therapy (e.g., recanalization) has been proven to
prevent cerebral edema and improve therapeutic outcomes in
patients with acute ischemic stroke (11,12). In rodent studies,
therapeutic hypothermia efficiently reduced the infarct size
in an ischemic stroke animal model when compared to
normothermia (13,14). Although the underlying mechanism
by which therapeutic hypothermia protects against cerebral
ischemia has not yet been fully clarified, hypothermia is
Figure 4 - IL-1b and CDK5 levels in a murine model of ischemic stroke. Animals were divided into control, ischemic stroke, or ischemic
stroke + hypothermia treatment groups. Serum IL-1b content (A) and IL-1b level in the brain tissue (B) were assessed by ELISA. Six
animals from each group were analyzed. (C, D) The protein expression of CDK5 and p-CDK5 in intracerebral ischemic penumbra or
control brain tissues was measured by Western blotting. Six animals from each group were analyzed. *po0.05; **po0.01.
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suggested to regulate the inflammatory responses by reducing
the expression of pro-inflammatory factors in mice with acute
ischemic stroke (15).
The pro-inflammatory cytokine IL-1b plays a crucial role
in the pathogenesis of ischemic stroke (16,17). Increased
generation of IL-1b in patients with ischemic stroke may
induce cell apoptosis, resulting in brain tissue injury in the
intracerebral ischemic penumbra area and ultimately enlar-
ging the area of cerebral infarction. In this study, hypother-
mia treatment efficiently decreased the IL-1b production
induced by inflammation in ischemic rodents as well as in
patients. Our findings are consistent with a previous study
revealing reduced IL-1b expression in stroke mice that
received hypothermia therapy (15).
CDK5 is a key molecule that mediates multiple signaling
pathways that lead to neuronal loss, including the autop-
hagy process (18,19), apoptosis (20,21), and neuronal death
processes (22,23). In particular, CDK5 activity during oxi-
dative stress has been found to contribute to the pathophy-
siology of various central nervous system disorders (24-26).
Our study revealed an increase in CDK5 in animals after
ischemic stroke. In addition, CDK5 signaling is closely
associated with inflammasome activation; as in primary
cultured cortical neurons, activation of the CDK5 pathway in
our study promoted the maturation and secretion of IL-1b
through activation of caspase 1. In addition, CDK5 activation
resulted in increased NF-kB activity in cultured neurons as
well as HEK293 cells. Compared to stroke animals, rats
receiving hypothermia therapy had a lower p-CDK5 level,
indicating that hypothermia suppressed the activation of the
CDK5 signaling pathway, consequently decreasing IL-1b
generation.
Consistent with previous clinical studies, our study of a
small cohort of patients showed clinical benefits of hypo-
thermia treatment. Hypothermia-treated patients showed a
better outcome than patients who received only standard of
care. This clinical benefit could result from the inhibitory
effects of hypothermia on the inflammatory response. Both the
brain and serum levels of IL-1b decreased with hypo-
thermia treatment, suggesting that hypothermia at least
partially blocks the inflammatory response signaling pathway.
However, a recent study found that the combination of mild
hypothermia and inhibition of CDK5 showed a trend toward
better outcomes (13), indicating that the effects of hypother-
mia are not limited to suppression of inflammatory responses.
In summary, our present study demonstrates that ther-
apeutic hypothermia exerts neuroprotection in ischemic stroke
via a novel mechanism. Therapeutic hypothermia suppresses
the abnormal activation of CDK5 in neurons following
ischemic stroke, which results in a reduction in NF-kB activity
and inhibition of caspase 1, ultimately decreasing the caspase
1-dependent production of IL-1b. In rats with ischemic stroke,
therapeutic hypothermia decreases the secretion of the pro-
inflammatory cytokine IL-1b, inhibits inflammatory respon-
ses, and prevents neuronal apoptosis, thereby providing
favorable therapeutic outcomes. Our findings may provide
clinical benefits to patients with acute ischemic stroke. Never-
theless, future studies will continue to explore the underlying
mechanism of neuroprotection induced by therapeutic
hypothermia.
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